Zealand Pharma

Denmark‑based Zealand Pharma develops peptide drugs for GI and metabolic disorders, markets the hypoglycemia injector Zegalogue, and runs Phase III glepaglutide for short bowel syndrome, partnering with Sanofi and Boehringer.

Headquarters: Denmark (DNK)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 440
HQ: Søborg

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ZEAL	Zealand Pharma Class A/S Cap: 30.0B \| P/E: 4.7	EQUITY	CPH	DKK	DK0060257814	Active	📈